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University of Liège, Liège, BelgiumAbstractIn Europe, most clinical babesiosis cases in humans have been attributed to Babesia divergens and Babesia sp. EU1. Babesia microti infection of
humans occurs mainly in the United States; although a case of autochthonous B. microti infection and serological evidence of infection have
been reported in Europe. The Indirect Fluorescent Antibody Test was used to screen sera from 199 anonymous Belgian patients with history
of tick bite and clinical symptoms compatible with a tick-borne disease. The serological screen detected positive reactivity in 9% (n = 18),
33.2% (n = 66), and 39.7% (n = 79) of the samples against B. microti, B. divergens, and Babesia sp. EU1, respectively. Thus, evidence of
contact among three potentially zoonotic species of Babesia and humans has been conﬁrmed in Belgium. Preventive action and
development of better diagnostic tools should help in prevention of clinical cases and to clarify the true burden of such infection for
individuals and public health.
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E-mail: llempereur@hotmail.comIntroductionBabesiosis is a tick-borne disease caused by different species of
intraerythrocytic protozoa classiﬁed within the genus Babesia.
In humans, clinical symptoms that develop early, or during a
mild Babesia sp. infection, can be confused with those of other
causes of undifferentiated febrile illness, showing high fever,
headaches, and myalgia. In acute infection, anaemia, icterus, and
haemoglobinuria are conspicuous, and this condition can beMicrobiol Infect 2015; 21: 96.e1–96.e7
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.07.004fatal. In Europe, three species with zoonotic capabilities have
been described [1]. Most clinical cases have been attributed to
Babesia divergens, a zoonotic species commonly found in cattle,
primarily in splenectomised or immunocompromised in-
dividuals [2], although some cases have recently been reported
in young immunocompetent patients [3]. Recently, a new
potentially zoonotic species of Babesia has been described.
Babesia sp. EU1 (proposed species nomenclature: B. venatorum)
was identiﬁed for the ﬁrst time in two asplenic human patients
[4], but has also been found to infect roe deer (Capreolus cap-
reolus) [5,6]. Babesia sp. EU1 is unable to reproduce in gerbils
(Meriones unguiculatus), providing evidence, together with evi-
dence of genotypic divergence, for recognition as a distinct
species from B. divergens [4].
Human cases caused by a third species, Babesia microti, have
been recorded in both spleen-intact and asplenic patients; it
usually presents as a relatively mild infection, except inious Diseases. Published by Elsevier Ltd. All rights reserved
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ural parasite of microtine rodents and occurs mainly in the
United States. However, a case of autochthonous B. microti
infection has been conﬁrmed in a German patient with an acute
myeloid leukaemia [7], and serological evidence of human B.
microti infections in a number of different European countries
has been reported (Table 1) [8–23].
In Belgium, B. divergens is known to be present in cattle in the
south of the country, but the disease is considered to be absent
from other regions [24]. The risk of human infection by Babesia
parasites in Belgium is generally considered to be low. How-
ever, a recent study identiﬁed the potentially zoonotic Babesia
species EU1 and B. microti in the Ixodes ricinus tick [8]. Together
with an older report of a human clinical case of babesiosis [21],
this study provided the impetus for an evaluation of potential
human contact with zoonotic Babesia parasites in Belgium. The
study was conducted by performing a retrospective serological
survey on samples obtained from humans in Belgium with a
history of tick bite.Materials and methodsHuman serum samples used in this study were collected and
sent by physicians to the laboratory for vector-borne diseases
in Neder-over-Heembeek, Belgium. In total, 199 sera from
anonymous Belgian patients with a history of tick bite in the
month prior to the onset of clinical symptoms compatible with
tick-borne disease (mainly fever and fatigue) were selected at
random from samples obtained between 2005 and 2010 (with
the approval of the ethical committee of the Liège University
Hospital, reference B707201010146).TABLE 1. Prevalence of zoonotic Babesia spp. (B. divergens, Babesia s
Source PCR
Feeding ticks collected on: Dog-Cat 1.1% (B. microti, Babesia sp. EU1)
Dog < 1% (B. divergens, Babesia sp. EU1)
Deer 2.1% (B. divergens, Babesia sp. EU1)
Deer 4.8% (B. microti, Babesia sp. EU1)
Bovine 14.6 % (Babesia sp. EU1)
Human 9.1% (B. microti)
Questing ticks: 2.5% (B. microti, Babesia sp. EU1)
0.8–11% (B. microti)
1.25% (Babesia sp. EU1)
1.1% (B. microti, B. divergens, Babesia s
Bovine
(B. divergens)
Deer
(Babesia sp. EU1)
26.9%
89.5%
Rodent
(B. microti)
11.8-15.9%
Human
IFAT, indirect ﬂuorescent antibody test; PCR, polymerase chain reaction.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology andAn indirect ﬂuorescent antibody test (IFAT) was used to
screen for the presence of antibodies against B. divergens,
Babesia sp. EU1, and B. microti in the 199 human serum samples.
A commercially available IFAT kit (Fuller Laboratories,
Worcester, MA, USA) was employed to detect IgG against B.
microti. According to the manufacturer’s speciﬁcations, samples
were scored as positive at a 1:64 or greater dilution. Positive
and negative controls provided by the manufacturer and an
additional positive control provided by the Reference Di-
agnostics Laboratory of the Center for Global Health (CDC,
Atlanta, GA, USA), were used to conﬁrm test accuracy.
The IFAT test for B. divergens was performed according to
Chauvin et al. [25], using as the antigenic source, blood of a
gerbil (Meriones unguiculatus) infected with B. divergens
(Rouen87, clone F5) initially isolated from an acute human case
of babesiosis. Babesia sp. EU1 antigen was derived from a
cloned parasite line (C201A), initially isolated from roe deer
and cultivated in vitro in sheep erythrocytes [5]. Serum samples
from both species were screened at dilutions of 1:8 and 1:16,
and were scored as positive at a 1:16 or greater dilution.
Positive control sera were collected from B. divergens-infected
cattle in France [26]. The human positive control serum was a
kind gift from Dr. Maija Lappalainen, Helsinki University (Hus-
Lab; Finland), and originated from a fatal clinical case attributed
to B. divergens in a 53-year-old man [27]. This serum was ﬁrst
screened for reactivity against B. divergens and Babesia sp. EU1
and demonstrated positive seroreactivity against B. divergens at
a titre of 1:512. Human negative control sera were selected
from a previous study (E. Moreau, unpublished data). Serum
obtained from a sheep experimentally infected by Babesia sp.
EU1 (clone C201A) was used as positive control for the Babesia
sp. EU1 test (E. Moreau, unpublished data). Cross reactivity ofp. EU1, and B. microti) in ticks, animals, and humans in Europe
Serology (IFAT) Country Reference
Belgium [8]
UK [9]
Belgium [10]
Germany [11]
Belgium [12]
The Netherlands [13]
Germany [11]
Switzerland [14]
France [15]
p. EU1) The Netherlands [16]
10.7–20% Belgium [12]
27% Norway [17]
Poland [18]
58.4% France [19]
Germany [11]
Slovenia [20]
7.8% (B. microti) Belgium [21]
5.4% (B. microti) Germany [22]
1.5% (B. microti) Switzerland [14]
6.2% (B. divergens) Germany [22]
17.7% (B. divergens) Slovenia [23]
Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 96.e1–96.e7
TABLE 3. Results obtained for samples from 199 patients
exposed to ticks from Belgium
Seropositive samples
n (%)
B. divergens 66 (33.2%)
Babesia sp. EU1 79 (39.7%)
B. microti 18 (9%)
Co-infections
B. divergens / Babesia sp. EU1 38 (19.1%)
B. microti / B. divergens 4 (2%)
B. microti/ Babesia sp. EU1 4 (2%)
B. microti / B. EU1 / B. divergens 2 (1%)
Babesia spp. 113 (56.8%)
Seropositivity was deﬁned using the following cut-off titres: B. microti IgG IFAT
1:64; B. divergens IgG IFAT 1:16; Babesia sp. EU1 IgG IFAT 1:16.
IFAT, indirect ﬂuorescent antibody test.
96.e3 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIsera among IFATs for B. divergens, Babesia sp. EU1, and B. microti
was tested by reaction of positive serum controls against the
respective antigen preparations. The blue-ﬂuorescent 4, 6-
diamindino-2-phenylindole nucleic acid stain (DAPI) was used
to highlight the presence of parasite nuclei on examination of
IFAT slides. Slides were mounted in 10 μL of mounting medium
containing 50% glycerol in phosphate-buffered saline, DAPI at
1 μg/mL, and phenylenediamine at 1 mg/mL, prior to the addi-
tion of a coverslip.
A multivariate logistic regression was used to investigate
possible effect of location, age, and sex of patients on their
serological status for Babesia spp. infection (STATA/SE Acad.
12, StataCorp, LP, College Station, TX, USA).ResultsA panel of human sera from 199 patients with history of a recent
tick bite was serologically screened. Ninety-ﬁve female and 103
male patients (1 unknown), mainly adults from 10 different
Belgian provinces, were included in this study (Table 2).
Positive reactivity against B. microti was detected in 9%
(n = 18) of the samples at a titre 1:64. Titration of B. microti-
positive serum samples generated a range between 1:64 and
1:512. The percentage of samples displaying positive reactivity
against B. divergens and Babesia sp. EU1 at a 1:16 dilution was
33.2% (n = 66) and 39.7% (n = 79), respectively. The percentage
of sera displaying positive reactivity for B. divergens or Babesia
sp. EU1 increased to 38.7% (n = 77) and 43.2% (n = 86),
respectively, of the samples, if the cut-off for a positive reaction
was taken at a 1:8 dilution. Co-infections were found for all
three Babesia species (Table 3).
The reactivity pattern displayed by the human positive
control sample and most of the B. divergens positive sera was
observed as ﬂuorescence concentrated at the apical poles on
the divergent angle of dividing parasites (Fig. 1). DAPI staining
showed that this structure did not co-localise with the nucleusTABLE 2. Sex, age and geographical locations associated with
the 199 selected human patients
Sex Age (years) Location (provinces)
Male 103  20 12 Antwerp 68
Female 95 21–40 63 Flemish Brabant 31
Unknown 1 41–60 85 Walloon Brabant 18
Total 199 >60 37 Brussels 13
Unknown 2 West Flanders 15
Total 199 East Flanders 10
Hainaut 13
Liège 8
Limburg 13
Luxembourg 0
Namur 4
Unknown 6
Total 199
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectof the parasite, and it was concluded that the serum antibody
was reacting most strongly against antigen located to the apical
complex (rhoptries/micronemes) (Fig. 2). This pattern of
reactivity was distinct from that obtained with positive control
serum derived from a bovine, where the pattern of reactivity
was evenly distributed across the whole organism, with staining
concentrated at the periphery in the absence of a detectable
apical structure (Fig. 3). Reactivity against Babesia sp. EU1 an-
tigen generated by positive sera from the samples of tick bite-
associated patients showed the same punctate pattern of ﬂuo-
rescence as obtained with the B. divergens slides.
To test for species speciﬁcity of the IFAT, each positive
control serum was cross-tested with each of the three antigen
preparations representing the different species. The results
showed that at the cut-off titre for positive reactivity (1:16 for
B. divergens and Babesia sp. EU1, and 1:64 for B. microti), each
control serum failed to react with antigen slides representing
either of the other two species. This result indicates that if a
serum sample from the obtained panel reacted with more than
one species by IFAT, then it can be considered that the patientFIG. 1. Indirect ﬂuorescent antibody test-reactivity of serum from a
human clinical case of babesiosis in Finland [27] at dilution 1:8 using B.
divergens parasites as antigen.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 96.e1–96.e7
FIG. 2. 4, 6-diamindino-2-phenylindole nucleic acid stain (DAPI)
staining of serum from a human clinical case of babesiosis in Finland [27]
at dilution 1:8 using B. divergens parasites as antigen.
FIG. 3. Reactivity of serum (dilution 1: 80) obtained from cattle in
France infected with B. divergens [26] using a B. divergens IFA test.
CMI Lempereur et al. Human babesiosis in Belgium 96.e4
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the same time or in succession.
Multivariate logistic regression showed an absence of a signif-
icant effect related to gender, whatever the Babesia spp (Table 4).
However, it did indicate that the risk of infection for Babesia sp.
EU1 per year may decrease as age increases; OR for the category
of patients older than 60 years is 0.21 (95%CI 0.05–0.93); p 0.04.
A higher risk of contact with B. microti was indicated for Namur
province, as a signiﬁcant association between positive reactivity
and Namur province was identiﬁed using Antwerp province as
reference; OR = 47.43 (95% CI 3.40–661.85); p 0.004.DiscussionThe retrospective serological survey performed in this study is
unique, as it focused on three potential zoonotic Babesia species
in Europe using a species-speciﬁc IFAT. The seroprevalence
shown for B. microti (9%) is in agreement with other European
surveys using samples from patients with a history of tick bite
or suspected to be suffering from another tick-borne disease:
11.1% in Germany [22] and 7.8% in Belgium [21].
The seroprevalence of 33.2% for B. divergens is higher than
previous surveys performed on samples from foresters in
Slovenia (17.7%) [23] or patients with recorded tick bites in
Germany (6.2%), while a recent survey in France generated a
very similar level of seropositive samples (E. Moreau, unpub-
lished data). Although an overestimation of the seroprevalence
may be possible based on subjective scoring of equivocal IFAT
reactivity as a positive, steps were taken to minimize this by
performing two independent readings and discarding results
obtained at a lower dilution than the deﬁned cut-off titre. The
source of antigen may also be a cause of variation among
seroprevalence surveys. Although no difference was seen when
antigen from human and bovine origin were compared, a higher
end-point titre has been obtained using antigen of human origin
[28]. Therefore, use of B. divergens of human origin as the
source of parasite antigen may result in a higher seroprevalence
percentage relative to bovine-derived antigen using the same
titre cut-off point for positivity. Furthermore, seroprevalence
for tick-borne infections will clearly be skewed toward positive
reactivity when using samples derived from patients with a
history of a tick bite and clinical symptoms compatible with
tick-borne disease, compared to surveys incorporating samples
from a wider range of human subjects. However, it has been
suggested that, in Europe, human babesiosis may occur more
often than previously indicated based on the results of the few
serological surveys performed to date [14,22,28].
The IFAT reactivity pattern associated with human sera
reacting against B. divergens parasites was found to beInfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 96.e1–96.e7
TABLE 4. Risk or protective factors associated with Babesia spp. seropositivity in Belgium according to multivariate logistic
regression
Babesia spp. Variable n OR (95% CI) p
Babesia sp. EU1 Gender Female 38 Reference
Male 41 0.87 (0.45–1.65) 0.66
Age of patients, years 20 7 Reference
21–40 27 0.57 (0.15–2.19) 0.42
41–60 36 0.54 (0.14–1.97) 0.35
>60 9 0.21 (0.05–0.93) 0.04
Location Antwerp 29 Reference
Flemish Brabant 11 0.74 (0.29–1.85) 0.52
Walloon Brabant 10 1.72 (0.59–5.04) 0.32
Brussels 5 0.76 (0.22–2.62) 0.22
West Flanders 7 1.07 (0.33–3.48) 0.91
East Flanders 2 0.38 (0.07–2.00) 0.26
Hainaut 6 1.34 (0.38–4.70) 0.65
Liège 2 0.20 (0.02–1.73) 0.14
Limburg 5 0.90 (0.25–3.26) 0.87
Namur 1 0.63 (0.05–6.83) 0.71
B. microti Gender Female 14 Reference
Male 4 3.35 (0.94–11.94) 0.06
Age of patients, years 40b 3 Reference
41–60 11 3.24 (0.79–13.32) 0.10
>60 4 1.82 (0.35–9.59) 0.48
Location Antwerp 4 Reference
Flemish Brabant 4 2.55 (0.55–11.88) 0.23
Walloon Brabant 2 1.56 (0.25–9.75) 0.63
Brussels 0 a
West Flanders 1 0.84 (0.08–8.54) 0.88
East Flanders 2 3.34 (0.49–22.91) 0.22
Hainaut 0 a
Liège 0 a
Limburg 1 1.06 (0.10–11.17) 0.96
Namur 3 47.43 (3.40–662) 0.004
B. divergens Gender Female 30 Reference
Male 36 0.59 (0.30–1.16) 0.13
Age of patients, years 20 3 Reference
21–40 15 0.87 (0.22–3.55) 0.85
41–60 32 1.07 (0.28–4.05) 0.92
>60 14 1.49 (0.35–6.37) 0.59
Location Antwerp 22 Reference
Flemish Brabant 6 0.59 (0.21–1.68) 0.32
Walloon Brabant 6 1.09 (0.35–3.33) 0.89
Brussels 5 1.24 (0.35–4.35) 0.74
West Flanders 6 1.55 (0.47–5.14) 0.47
East Flanders 3 0.95 (0.22–4.14) 0.94
Hainaut 3 0.74 (0.18–3.08) 0.68
Liège 4 2.43 (0.53–11.07) 0.25
Limburg 4 0.89 (0.21–3.76) 0.88
Namur 3 7.11 (0.66–76.50) 0.11
n, number of seropositive patients;.
aAll patients from this province were seronegative.
bCategories of age 20 years and between 21 and 40 years were merged as all patients of the ﬁrst category were seronegative.
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suggest the presence of immunodominant antigens localized in
the apical complex of the parasite. B. divergens merozoite sur-
face antigen (Bd37) is known to be a major immunodominant
protein, and while this immunodominant antigen could be
detected by immunoblotting with bovine serum samples, it was
not detected with the human samples of this study (data not
shown). The reason for this result is not clear, although poly-
morphism of Bd37 has been reported [29].
The reported study together with a related survey per-
formed in France (E. Moreau, unpublished data) are the ﬁrst
to evaluate Babesia sp. EU1 seroprevalence using as antigen a
conﬁrmed Babesia sp. EU1 cloned line isolated from an in vivo
infection. No clear evidence of cross reactivity was observed
between antigen preparations employed for each IFAT when
using positive control serum speciﬁc for each of the threeClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectspecies. Given the close phylogenetic relationship between B.
divergens and Babesia sp. EU1, this result could be viewed as
surprising. While Duh and collaborators [28] described an
absence of cross reactivity of serum against B. divergens with B.
microti, cross reactivity of sera between B. divergens and
Babesia sp. EU1 has been reported [4,28]. It may be that,
previously, IFAT positive results have scored potential B.
divergens and Babesia sp. EU1 co-infection as cross recognition.
In the present study, 41 patients positive for Babesia sp. EU1
were scored as negative for B. divergens. This result indicates
that the antigenic epitopes predominantly recognized by these
and the control sera have diverged between the two species
to the extent that cross recognition does not occur. A
conﬁrmed lack of cross reactivity would lend further support
to the description of Babesia sp. EU1 as a distinct species of
Babesia.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 96.e1–96.e7
CMI Lempereur et al. Human babesiosis in Belgium 96.e6The number of potential co-infections (n = 38) identiﬁed in
this study based on co-recognition of both B. divergens and
Babesia sp. EU1 by individual sera was high. Frequent co-
infections with B. divergens and Babesia sp. EU1 may be
possible, as these species share the same tick vector. In addi-
tion, the possibility of maintained transmission of B. divergens
across tick stages and transovarially into the next generation
could promote co-infection of ticks [10]. Furthermore, deer
have been recognised as the main reservoir host for Babesia sp.
EU1 and, while still controversial, may act as hosts for
B. divergens [5]. The presence of the two Babesia species in the
same reservoir host would increase the probability of co-
transmission. Further studies are required to show that re-
sults based on recognition of both species by an antibody test
correlate with molecular data validating co-infection of the
mammalian host.
Multivariate logistic regression analysis showed that the risk
of being seropositive for B. microti was higher in Namur prov-
ince than the other provinces. This result has to be treated with
caution, as only four samples from Namur were analysed. In
addition, the apparent association indicating a lower chance of
Babesia sp. EU1 infection in the older group of patients may be
explained by differences in leisure activity or a greater aware-
ness of tick-borne diseases by older patients, and consequently,
faster removal of attached ticks that could reduce parasite
transmission. Alternatively, differences in the acquired immune
response may play a role, with adults more effective at reducing
time of tick feeding, again reducing the chance of parasite
transmission [30].
Unfortunately, clinical data and information about work and
leisure activities of patients were not available, and data conﬁ-
dentiality did not allow determination of risk factors that may
be associated with tick contact and transmission of infection.
At present, IFAT, although not ideal, is the best available test
to evaluate the occurrence of Babesia spp. transmission to
humans, since these parasites are usually eliminated rapidly by
the immune system, leaving only a serological trace. Analysis
using other serological tests, ELISA and Western blot, were
attempted in this study, but the major immunodominant
merozoite surface antigen could not be detected using the
human sera (unpublished observation). To fully evaluate the
level of exposure of the human population in Belgium to Babesia
parasites, the development of a “home-made” IFAT test using
molecularly validated European strain of B. microti and Babesia
sp. EU1 derived from human cells as antigen is required. The
paucity of European B. microti and Babesia sp. EU1 human
clinical cases, however, means that routine provision of a
standard antigen would be extremely difﬁcult without an
available culture system. Moreover, the use of the commercial
IFAT kit based on a B. microti strain from the United StatesClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology andimposes signiﬁcant costs and precludes the use of this test for a
large-scale serological survey, which may lead to an underesti-
mation of human B. microti infection in Europe. Such an un-
derestimation could have potential consequences, given that it
is now recognized that contamination of human blood with B.
microti is a potential risk during transfusion and that B. microti
infections are now notiﬁable in the United States [31].
In summary, the presence of the three potentially zoonotic
species of Babesia in Belgium has been supported in this study,
by provision of evidence for human contact with B. divergens,
Babesia sp. EU1, and B. microti. Thus, in Belgium, as in other
European countries, babesiosis can be considered as a potential
threat for human health, especially in splenectomised and
immunocompromised individuals. Preventive action against tick
attachment together with improved awareness of babesiosis by
physicians and development of better diagnostic tools should
help in prevention of clinical cases and to assess the risk to
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